170
Participants
Start Date
August 31, 2020
Primary Completion Date
November 30, 2025
Study Completion Date
December 31, 2025
CFI-402411
CFI-402411 is administered orally once daily. The starting dose is 80 mg/day for escalation arms and the recommended dose for the expansion arms.
Pembrolizumab
Pembrolizumab will be given at its labeled dose and schedule, 200 mg administered as an intravenous infusion over 30 minutes every 3 weeks.
Virginia Cancer Specialist, Fairfax
Florida Cancer Specialists, Sarasota
SCRI - Nashville, Nashville
START - Mid-West, Grand Rapids
MD Anderson, Houston
START - San Antonio, San Antonio
The Angeles Clinic, Los Angeles
University of California San Diego, La Jolla
Yale Cancer Center, New Haven
Cross Cancer Institute, Edmonton
The Ottawa Hospital, Ottawa
Princess Margaret Cancer Centre, Toronto
Prince of Wales Hospital, Shatin
TIO Discovery Engine
UNKNOWN
Treadwell Therapeutics, Inc
INDUSTRY